Mayzent 0.25 mg film-coated tablets

DRUG2 trials

Sponsors

Azienda Ospedaliera Universitaria Integrata Verona

Conditions

Active progressive multiple sclerosis course after an initial relapse clinical coursepatients with secondary progressive MS

Phase 4

Exploring the effect of a novel therapy on chronic intrathecal inflammation in patients with active progressive multiple sclerosis

RecruitingCTIS2024-512283-65-00

Azienda Ospedaliera Universitaria Integrata Veronapatients with secondary progressive MS

Start: 2023-05-29Target: 40Updated: 2024-08-06

Effect of siponimod on relevant imaging and immunological hallmarks of progressive multiple sclerosis

RecruitingCTIS2024-518374-13-00

Azienda Ospedaliera Universitaria Integrata VeronaActive progressive multiple sclerosis course after an initial relapse clinical course

Start: 2022-02-28Target: 60Updated: 2024-11-05